APA (7th ed.) Citation

Pathil-Warth, A., Müller, J., Ludwig, J. M., Wang, J., Warth, A., Chamulitrat, W., & Stremmel, W. (2014). Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling. British journal of pharmacology, 171(22), . https://doi.org/10.1111/bph.12837

Chicago Style (17th ed.) Citation

Pathil-Warth, Anita, Jan Müller, Johannes Maximilian Ludwig, Jiliang Wang, Arne Warth, Walee Chamulitrat, and Wolfgang Stremmel. "Ursodeoxycholyl Lysophosphatidylethanolamide Attenuates Hepatofibrogenesis by Impairment of TGF-β1/Smad2/3 Signalling." British Journal of Pharmacology 171, no. 22 (2014). https://doi.org/10.1111/bph.12837.

MLA (9th ed.) Citation

Pathil-Warth, Anita, et al. "Ursodeoxycholyl Lysophosphatidylethanolamide Attenuates Hepatofibrogenesis by Impairment of TGF-β1/Smad2/3 Signalling." British Journal of Pharmacology, vol. 171, no. 22, 2014, https://doi.org/10.1111/bph.12837.